BURLINGTON, Mass., May 28, 2014 /PRNewswire/ -- Decision Resources Group finds that the mature global cardiac rhythm management (CRM) device market will be driven by favorable demographics and the launch of premium-priced novel devices such as magnetic resonance imaging (MRI)-compatible devices, leadless pacemakers and subcutaneous implantable cardioverter defibrillators (S-ICDs). However, these new technologies will have a minor effect on the market overall because they do not expand the patient population and more competition is anticipated in these categories, resulting in price erosion in the long term. As a result, the global CRM device market—including the United States, France, Germany, Italy, Spain, the United Kingdom and Japan—will expand until 2019, at which point the market will begin to decline.

Other key findings from the Medtech 360 report entitled Global Markets for Cardiac Rhythm Management Devices 2014:

  • MRI-compatible devices: The company that has made the greatest strides in developing MRI-compatible devices is BIOTRONIK, which has European approval for an MRI-compatible implantable cardioverter defibrillator and has plans to extend this capability to its other CRM devices.
  • Leadless pacemakers: Leadless pacemakers are a major innovation in the pacemaker market. A fraction of the size of conventional pacemakers, these devices are thought to significantly reduce the risk of infection and improve the safety of pacemakers in general because the leads are the most likely component to fail. To date, St. Jude Medical's Nanostim is the only product with approval in Europe and the U.S., but Medtronic is poised to follow suit with its Micra device.
  • S-ICDs: S-ICDs represent another innovation that promises to reduce complications associated with leads because they do not require electrodes to be placed inside the heart. Boston Scientific has launched the first S-ICD in the U.S.; however, sales of its product have been plagued by insufficient supply.

Comments from Decision Resources Group Analyst Leila Bautista:

  • "Until these novel devices that reduce the risk of lead complications are widely available, there will continue to be considerable interest in lead extraction devices. Powered lead extraction devices will be used in the majority of procedures because they have been shown to be most effective at separating the lead from surrounding scar tissue; however, less expensive mechanical devices will continue to be used in cases where reimbursement is not provided, such as in France."
  • "Clinical trial results have had a significant impact on the cardiac resynchronization therapy (CRT) device market in recent years, and guidelines have been updated globally to reflect this new evidence. Despite a narrower set of indications, CRT adoption will still be rapid through 2022 because clinical evidence has been favorable in the appropriate indications."

Additional Resources:

  • Leila Bautista has written a blog on the subject, which can be found here.
  • Decision Resources Group's Marketrack, which provides market share data by brand for the CRM device market, can be found here.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com 

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Glivec is the Favored First-Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myelogenous Leukemia, According to Surveyed European Hematological Oncologists

View Now